<div id="readability-page-1"><p>Causeway Capital Management LLC lessened its stake in shares of  Smith &amp; Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 30.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 572,532 shares of the medical equipment provider's stock after selling 248,476 shares during the period. Causeway Capital Management LLC owned about 0.13% of Smith &amp; Nephew SNATS worth $20,777,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Smith &amp; Nephew SNATS</strong> alerts:</span></p></div><ul><li>Santa Rally comes early for these stocks</li></ul><p>A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNN. JPMorgan Chase &amp; Co. raised its holdings in shares of  Smith &amp; Nephew SNATS by 6,663.4% in the 2nd quarter. JPMorgan Chase &amp; Co. now owns 1,210,655 shares of the medical equipment provider's stock worth $37,082,000 after purchasing an additional 1,192,755 shares during the period.  ABC Arbitrage SA lifted its holdings in  Smith &amp; Nephew SNATS by 1,063.4% during the 2nd quarter. ABC Arbitrage SA now owns 898,635 shares of the medical equipment provider's stock worth $27,525,000 after purchasing an additional 821,393 shares in the last quarter.  Todd Asset Management LLC purchased a new position in  Smith &amp; Nephew SNATS during the third quarter valued at approximately $26,319,000.  Goldman Sachs Group Inc. grew its position in shares of  Smith &amp; Nephew SNATS by 49.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider's stock valued at $50,255,000 after purchasing an additional 583,809 shares in the last quarter.  Finally, BNP Paribas Financial Markets increased its stake in  Smith &amp; Nephew SNATS by 365.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 644,525 shares of the medical equipment provider's stock worth $19,742,000 after acquiring an additional 505,934 shares during the last quarter. 25.64% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Smith &amp; Nephew SNATS Trading Down 0.8%</h2><p>Shares of SNN stock opened at $34.03 on Tuesday. The stock has a fifty day moving average of $34.45 and a 200 day moving average of $34.89. Smith &amp; Nephew SNATS, Inc. has a 52 week low of $23.91 and a 52 week high of $38.79. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60. </p><h2>Smith &amp; Nephew SNATS Dividend Announcement</h2><ul><li>Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand</li></ul><p>The business also recently declared a  dividend, which will be paid on Wednesday, May 27th. Investors of record on Friday, March 27th will be given a dividend of $0.482 per share. The ex-dividend date is Friday, March 27th. This represents a dividend yield of 281.0%. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of equities analysts have commented on the stock. Weiss Ratings  reissued a &#34;hold (c+)&#34; rating on shares of Smith &amp; Nephew SNATS in a research note on Wednesday, January 21st. Kepler Capital Markets raised Smith &amp; Nephew SNATS to a &#34;strong-buy&#34; rating in a research note on Monday, November 17th. Wall Street Zen upgraded Smith &amp; Nephew SNATS from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday. Canaccord Genuity Group lifted their price target on shares of Smith &amp; Nephew SNATS from $34.00 to $35.00 and gave the stock a &#34;hold&#34; rating in a research note on Thursday, March 5th. Finally, Royal Bank Of Canada lowered shares of Smith &amp; Nephew SNATS from an &#34;outperform&#34; rating to a &#34;sector perform&#34; rating in a report on Monday, December 15th. One investment analyst  has rated the stock with a Strong Buy rating and five have issued  a Hold rating to the company. According to data from MarketBeat, Smith &amp; Nephew SNATS currently has an average rating of &#34;Hold&#34; and a consensus price target of $36.25.</p><ul><li>3 Healthcare Dividend Payers With Big Price Growth</li></ul><p><b>Read Our Latest Report on Smith &amp; Nephew SNATS</b></p><h2>Smith &amp; Nephew SNATS Profile</h2> (Free Report)<p>Smith &amp; Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.  </p><p>In its orthopaedics business, Smith &amp; Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Smith &amp; Nephew SNATS</li><li>The Market Just Split in Two (URGENT)</li><li>Buy this Gold Stock Before May 15th, 2026</li><li>J.P. Morgan is betting on this coin</li><li>Central banks just did something they haven’t done since 1967</li><li>Ticker Revealed: Pre-IPO Access to &#34;Next Elon Musk&#34; Company</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNOTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNOTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Smith &amp; Nephew SNATS Right Now?</h2><p>Before you consider Smith &amp; Nephew SNATS, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith &amp; Nephew SNATS wasn't on the list.</p><p>While Smith &amp; Nephew SNATS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Causeway Capital Management LLC reduced its stake in Smith & Nephew SNATS, Inc. by 30.3%, selling 248,476 shares in Q3, now holding 572,532 shares valued at $20.8 million. Other institutional investors, including JPMorgan and Goldman Sachs, have also adjusted their positions significantly. Smith & Nephew's stock opened at $34.03, with a 52-week range of $23.91 to $38.79. The company declared a dividend of $0.482 per share, with a yield of 281.0%. Analysts have mixed ratings, with an average consensus of "Hold" and a price target of $36.25.</p>

Causeway Capital Management LLC Sells 248,476 Shares of Smith & Nephew SNATS, Inc. $SNN